Your browser doesn't support javascript.
SARS-CoV-2 engages inflammasome and pyroptosis in human primary monocytes.
Ferreira, André C; Soares, Vinicius Cardoso; de Azevedo-Quintanilha, Isaclaudia G; Dias, Suelen da Silva Gomes; Fintelman-Rodrigues, Natalia; Sacramento, Carolina Q; Mattos, Mayara; de Freitas, Caroline S; Temerozo, Jairo R; Teixeira, Lívia; Damaceno Hottz, Eugenio; Barreto, Ester A; Pão, Camila R R; Palhinha, Lohanna; Miranda, Milene; Bou-Habib, Dumith Chequer; Bozza, Fernando A; Bozza, Patrícia T; Souza, Thiago Moreno L.
  • Ferreira AC; Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil. tmoreno@cdts.fiocruz.br.
  • Soares VC; Laboratório de Pesquisa Pré-clínica-Universidade Iguaçu - UNIG, Nova Iguaçu, RJ, Brazil. tmoreno@cdts.fiocruz.br.
  • de Azevedo-Quintanilha IG; National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz, Rio de Janeiro, RJ, Brazil. tmoreno@cdts.fiocruz.br.
  • Dias SDSG; Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil.
  • Fintelman-Rodrigues N; Program of Immunology and Inflammation, Federal University of Rio de Janeiro, UFRJ, Rio de Janeiro, RJ, Brazil.
  • Sacramento CQ; Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil.
  • Mattos M; Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil.
  • de Freitas CS; Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil.
  • Temerozo JR; National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz, Rio de Janeiro, RJ, Brazil.
  • Teixeira L; Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil.
  • Damaceno Hottz E; National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz, Rio de Janeiro, RJ, Brazil.
  • Barreto EA; Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil.
  • Pão CRR; National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz, Rio de Janeiro, RJ, Brazil.
  • Palhinha L; Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil.
  • Miranda M; National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz, Rio de Janeiro, RJ, Brazil.
  • Bou-Habib DC; Laboratório de Pesquisas sobre o Timo, IOC, Fiocruz, Rio de Janeiro, RJ, Brazil.
  • Bozza FA; National Institute for Science and Technology on Neuroimmunomodulation, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, RJ, Brazil.
  • Bozza PT; Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil.
  • Souza TML; Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil.
Cell Death Discov ; 7(1): 43, 2021 Mar 01.
Article in English | MEDLINE | ID: covidwho-1111974
ABSTRACT
Infection by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been associated with leukopenia and uncontrolled inflammatory response in critically ill patients. A better comprehension of SARS-CoV-2-induced monocyte death is essential for the identification of therapies capable to control the hyper-inflammation and reduce viral replication in patients with 2019 coronavirus disease (COVID-19). Here, we show that SARS-CoV-2 engages inflammasome and triggers pyroptosis in human monocytes, experimentally infected, and from patients under intensive care. Pyroptosis associated with caspase-1 activation, IL-1ß production, gasdermin D cleavage, and enhanced pro-inflammatory cytokine levels in human primary monocytes. At least in part, our results originally describe mechanisms by which monocytes, a central cellular component recruited from peripheral blood to respiratory tract, succumb to control severe COVID-19.

Full text: Available Collection: International databases Database: MEDLINE Language: English Journal: Cell Death Discov Year: 2021 Document Type: Article Affiliation country: S41420-021-00428-w

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Language: English Journal: Cell Death Discov Year: 2021 Document Type: Article Affiliation country: S41420-021-00428-w